Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.

Dai F, Zhang Y, Zhu X, Shan N, Chen Y.

Gynecol Oncol. 2013 Nov;131(2):451-9. doi: 10.1016/j.ygyno.2013.07.112. Epub 2013 Aug 8.

PMID:
23933187
[PubMed - indexed for MEDLINE]
2.

Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.

Dai F, Zhang Y, Zhu X, Shan N, Chen Y.

Target Oncol. 2012 Dec;7(4):217-25. doi: 10.1007/s11523-012-0236-7. Epub 2012 Nov 20.

PMID:
23179556
[PubMed - indexed for MEDLINE]
3.

The mechanism involved in the loss of PTEN expression in NSCLC tumor cells.

Li G, Zhao J, Peng X, Liang J, Deng X, Chen Y.

Biochem Biophys Res Commun. 2012 Feb 17;418(3):547-52. doi: 10.1016/j.bbrc.2012.01.065. Epub 2012 Jan 21.

PMID:
22290228
[PubMed - indexed for MEDLINE]
4.

Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.

Liu N, Zhou C, Zhao J, Chen Y.

Cancer Invest. 2012 Oct;30(8):577-82. Epub 2012 Jul 19.

PMID:
22812695
[PubMed - indexed for MEDLINE]
5.

The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells.

Wang X, Zhao J, Huang J, Tang H, Yu S, Chen Y.

Biochem Biophys Res Commun. 2012 Aug 17;425(1):51-7. doi: 10.1016/j.bbrc.2012.07.047. Epub 2012 Jul 20.

PMID:
22820191
[PubMed - indexed for MEDLINE]
6.

[Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].

Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S.

Zhonghua Yi Xue Za Zhi. 2002 Sep 10;82(17):1207-10. Chinese.

PMID:
12475412
[PubMed - indexed for MEDLINE]
7.

Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.

Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, Ahn SG, Yoon JH, Kang KW.

Breast Cancer Res Treat. 2011 Nov;130(1):73-83. doi: 10.1007/s10549-010-1304-2. Epub 2010 Dec 18.

PMID:
21170675
[PubMed - indexed for MEDLINE]
8.

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

Lee S, Choi EJ, Jin C, Kim DH.

Gynecol Oncol. 2005 Apr;97(1):26-34.

PMID:
15790433
[PubMed - indexed for MEDLINE]
9.

Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.

Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK.

Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.

PMID:
23074172
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.

Tang XH, Deng S, Li M, Lu MS.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):676-80. doi: 10.1016/j.bbrc.2012.05.052. Epub 2012 May 17.

PMID:
22609777
[PubMed - indexed for MEDLINE]
11.

MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.

Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS.

BMC Cancer. 2010 Jan 31;10:27. doi: 10.1186/1471-2407-10-27.

PMID:
20113523
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.

Yan X, Fraser M, Qiu Q, Tsang BK.

Gynecol Oncol. 2006 Aug;102(2):348-55. Epub 2006 Mar 20.

PMID:
16545436
[PubMed - indexed for MEDLINE]
13.

c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.

Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.

Oncogene. 2013 May 30;32(22):2767-81. doi: 10.1038/onc.2012.290. Epub 2012 Jul 16.

PMID:
22797058
[PubMed - indexed for MEDLINE]
14.

Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kearsley JH, Li Y.

PLoS One. 2011;6(9):e24405. doi: 10.1371/journal.pone.0024405. Epub 2011 Sep 9.

PMID:
21931707
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.

Nakashima H, Miyake K, Clark CR, Bekisz J, Finbloom J, Husain SR, Baron S, Puri RK, Zoon KC.

Cancer Immunol Immunother. 2012 Jul;61(7):1081-92. doi: 10.1007/s00262-011-1152-x. Epub 2011 Dec 13.

PMID:
22159517
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

miR-29b regulates migration of human breast cancer cells.

Wang C, Bian Z, Wei D, Zhang JG.

Mol Cell Biochem. 2011 Jun;352(1-2):197-207. doi: 10.1007/s11010-011-0755-z. Epub 2011 Feb 26.

PMID:
21359530
[PubMed - indexed for MEDLINE]
17.

Growth suppression of human lung cancer cells and implanted tumors by adenovirus-mediated transfer of the PTEN gene.

Chen Z, Yang J.

J Huazhong Univ Sci Technolog Med Sci. 2010 Apr;30(2):149-54. doi: 10.1007/s11596-010-0203-4. Epub 2010 Apr 21.

PMID:
20407863
[PubMed - indexed for MEDLINE]
18.

Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels.

Liu P, Gou M, Yi T, Xie C, Qi X, Zhou S, Deng H, Wei Y, Zhao X.

Oncol Rep. 2012 Feb;27(2):363-70. doi: 10.3892/or.2011.1550. Epub 2011 Nov 11.

PMID:
22086394
[PubMed - indexed for MEDLINE]
19.

[The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].

Song Y, Shen K, Yu JR.

Zhonghua Yi Xue Za Zhi. 2007 Nov 6;87(41):2919-24. Chinese.

PMID:
18261307
[PubMed - indexed for MEDLINE]
20.

A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways.

Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y.

BMC Complement Altern Med. 2013 Feb 15;13:33. doi: 10.1186/1472-6882-13-33.

PMID:
23410205
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk